Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US will go public soon. The estimated IPO date is March 3, 2025.

IPO Price Range

$4.00 - $5.00

Shares Offered

4,500,000

Deal Size

$20.25M

APUS Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	-	0.65	0.27
Research & Development	-	0.1	0.37
Operating Expenses	-	0.75	0.64
Operating Income	-1.36	-0.75	-0.64
Interest Expense / Income	0.06	0.03	0.03
Pretax Income	-1.42	-0.78	-0.67
Net Income	-1.42	-0.78	-0.67
Free Cash Flow	-1.06	-0.63	-0.45
EBITDA	-1.36	-0.75	-0.64
EBIT	-1.36	-0.75	-0.64

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).